BACKChild Synbiotic Formula
[Licensing negotiation in progress]
[Invitation for Expression of Interest- Deadline: 5 January 2023]
Invitation for Expression of Interest for “Child Synbiotic Formula” Technology
We are inviting expressions of interest (EoI) for commercializing “Child Synbiotic Formula” technology. The innovation is developed by Professor NG Siew Chien, Professor of Department of Medicine & Therapeutics of The Chinese University of Hong Kong (CUHK Reference: 22/MED/1187).
The Technology
The purpose of this invention is to define the composition of a synbiotic for prevention an/or treatment of infection including respiratory infctions, including Coronavirus disease-2019 (COVID-19), influenza, respiratory syncytial virus, and to improve immunity in infant and children, as well as to treat and prevent atopic dermatitis in infant and children.
Commercialization
The technology is now available for licensing on an exclusive basis. In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development. In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society. Previous or existing business involvement and experience in this area is a plus.
This invitation of expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.
Child Synbiotic Formula
[Licensing negotiation in progress]
[Invitation for Expression of Interest- Deadline: 5 January 2023]
Invitation for Expression of Interest for “Child Synbiotic Formula” Technology
We are inviting expressions of interest (EoI) for commercializing “Child Synbiotic Formula” technology. The innovation is developed by Professor NG Siew Chien, Professor of Department of Medicine & Therapeutics of The Chinese University of Hong Kong (CUHK Reference: 22/MED/1187).
The Technology
The purpose of this invention is to define the composition of a synbiotic for prevention an/or treatment of infection including respiratory infctions, including Coronavirus disease-2019 (COVID-19), influenza, respiratory syncytial virus, and to improve immunity in infant and children, as well as to treat and prevent atopic dermatitis in infant and children.
Commercialization
The technology is now available for licensing on an exclusive basis. In order to fully realize the benefit of the technology, we expect substantial investment is necessary to enable further research and development. In addition to the financial commitment, the licensee is expected to have the appropriate expertise as well as plans in marketing and strategizing the end product to ensure successful transfer of the technology to the society. Previous or existing business involvement and experience in this area is a plus.
This invitation of expression of interest is without prejudice. We also stress that this invitation is not a tender, and the University is not bound to accept any offer, or to accept the highest monetary offer, as there are additional considerations (such as the widest possible benefit to the community) that we, as a public institution, will need to take into consideration.
N/A
Erika Yuen
Office of Research and Knowledge Transfer Services
NG Siew Chien
CHAN Ka Leung
XU Zhilu
HU Jielun
TANG Wing Yan
FAN Sze Leung Rachel
N/A